Key result
RBPI23 reduced the endotoxin-induced activation of the fibrinolytic and coagulation systems after low-dose endotoxin infusion compared to placebo.
Why the study?
Does rBPI23 reduce endotoxin-induced activation of the fibrinolytic and coagulation systems in human volunteers?
RCT (n=8)
Blinded
Does rBPI23 reduce endotoxin-induced activation of the fibrinolytic and coagulation systems in human volunteers?
rBPI23 partially prevents the activation of fibrinolytic and coagulation pathways induced by low-dose endotoxin in humans.
Answers are grounded in this paper and cite their sources.
rBPI23 attenuates endotoxin-driven coagulopathy in volunteers; extends preclinical data and supports trials in clinical sepsis.
A recombinant endotoxin-neutralizing protein, rBPI23, was shown to partially prevent endotoxin-induced activation of the fibrinolytic and coagulation systems in experimental endotoxemia in humans. In a placebo-controlled, blinded crossover study, eight volunteers were challenged twice with an intravenous bolus injection of endotoxin (40 EU/kg of body weight) and concurrently received either rBPI23 (1 mg/kg) or placebo (human serum albumin, 0.2 mg/kg). rBPI23 treatment significantly lowered the endotoxin-induced fibrinolytic response, ie, reduced the release of tissue-type plasminogen activator, urokinase-type plasminogen activator, plasminogen activator inhibitor antigen, and complex formation of plasmin alpha 2-antiplasmin (P = .0078 for each). Plasminogen activator inhibitor activity was also reduced, but not significantly according to the Hochberg method (P = .0304). The endotoxin-induced activation of the procoagulant state as reflected by increase in F1 + 2 fragments and TAT complexes was blunted by rBPI23 infusion (P = .0391 [not significant according to the Hochberg method] and .0078, respectively). These results indicate that rBPI23 is capable of reducing both the activation of the fibrinolytic and the coagulation systems after low-dose endotoxin infusion in humans.
No takes yet. Share an insight, caveat, or question.
Mohlen et al. (1995) conducted an RCT in Experimental endotoxemia (n=8). rBPI23 vs. Placebo (human serum albumin, 0.2 mg/kg) was evaluated on Endotoxin-induced fibrinolytic response (release of t-PA, u-PA, PAI antigen, and plasmin alpha 2-antiplasmin complex) (p=.0078). RBPI23 reduced the endotoxin-induced activation of the fibrinolytic and coagulation systems after low-dose endotoxin infusion compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: